The preclinical division of Vimta Labs is driven by a mission to develop reliable and reproducible scientific data while maintaining a healthy balance between animal ethics, welfare and experimentation.
The main core areas in which Vimta focuses to render drug discovery services to pharmaceutical and biotech companies are
The experiments will be designed to generate adequate and robust data in exploratory and regulatory areas using both in vitro and in vivo models. Preclinical evaluation studies will be conducted in different modules as per the need of the sponsor in accordance with national and international guidelines (ICH and US FDA, OECD). Screening of NCEs using in vitro systems to facilitate lead optimization and lead identification and in vivo models like mice, rats, guinea pigs, rabbits and beagle dogs through different routes for proof of principle, fast track kinetics and safety assessment with GLP compliance.
Toxicology division was started in the year 1992 at Vimta’s cherlapally facility.
This facility was certified for GLP by Standard Australia Quality Assurance Services (SAQAS) in the year 1997.
Our initial focus was on agricultural & industrial chemicals. From 2000, focus shifted to pharma and biotech industries.
To meet the current requirements in the area of drug discovery research, activities at cherlapally facility were suspended in the year 2005 and present facility was started in the year 2006 at S.P. Biotech Park, Genome valley, Turkapally.
The new 33, 000 square feet state of the art facility with full set of preclinical services was inaugurated in August 2009.